Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069505 | 0.88 | ITGB1 (0.43) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7069229 | 0.86 | PPARG (0.52) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7067684 | 0.85 | MAOB (0.47) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7069255 | 0.84 | MME (0.39) | ALOX5TPH1MMEACECPA1 | |
| SCHEMBL7065958 | 0.83 | MAOB (0.46) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7066077 | 0.83 | MAOB (0.47) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7066051 | 0.82 | PPARG (0.47) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7070013 | 0.82 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL7070132 | 0.82 | KMT2A (0.49) | MAOBPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7068771 | 0.82 | PPARG (0.55) | MAOBPPARAPPARGCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | MAOB 2959/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.